GSK And Novartis Hit With $3m Fine In Australia For Misleading Voltaren Claims
Marketing Voltaren Osteo Gel as more effective for treating osteoarthritis than the identically formulated Voltaren Emugel has landed GSK and Novartis with a substantial fine for breaching Australian Consumer Law.
You may also be interested in...
GSK has admitted misleading Australian consumers with the marketing of its Voltaren range by claiming Osteo Gel was specifically formulated for treating osteoarthritis conditions, and was more effective than Emulgel to treat those conditions, when the two products were identically formulated. While a change to Osteo Gel's packaging has since satisfied Australia's Federal Court, GSK is still facing a financial penalty for its earlier conduct.
P&G's decision to offload its Haliborange children's supplement line will not lead to reduced competition in the UK market, according to the regulator.
GNC has won a long running dispute over the use of its "GNC Live Well" trademark in Europe after a challenge by Lithuanian pharmacy retailer Euroapotheca was rejected by the European General Court.